Cipla Ltd, India's fourth-largest drugmaker by sales, said on Friday it has agreed to buy two generics businesses in the United States in an all-cash deal worth $550 million to get access to a wide......
With marketing licence deals being struck virtually every week in the Indian pharmaceutical sector in the last few months and more in the offing, Indian companies are gearing up to strengthen their......
Glenmark Pharmaceuticals would soon close its second discovery molecule outlicensing deal with a multinational drug company. The lead molecule - GRC 8200, a promising drug for treatment of type 2......